Pharmacology and Toxicology of Major Constituents of Marijuana—On the Metabolic Activation of Cannabinoids and Its Mechanism
- 1 January 2003
- journal article
- Published by Informa UK Limited in Journal of Toxicology: Toxin Reviews
- Vol. 22 (4), 577-589
- https://doi.org/10.1081/txr-120026915
Abstract
Many oxidative metabolites of tetrahydrocannabinols (THCs), active components of Cannabis sativa L. (Cannabinaceae), were pharmacologically potent, and 11‐hydroxy‐THCs, 11‐oxo‐Δ8‐THC, 7‐oxo‐Δ8‐THC, 8β,9β‐epoxyhexahydrocannabinol (EHHC), 9α,10α‐EHHC and 3'‐hydroxy‐Δ9‐THC were more active than THC in pharmacological effects such as catalepsy, hypothermia and barbiturate synergism in mice, indicating that these metabolites are active metabolites of THCs. Cannabidiol (CBD), another major component, was biotransfomred to two novel metabolites, 6‐hydroxymethyl‐Δ9‐THC and 3‐pentyl‐6, 7, 7a, 8, 9, 11a‐hexahydro‐1, 7‐dihydroxy‐7,10‐dimethyldibenzo[b,d]oxepin (PHDO) through 8R,9‐epoxy‐CBD and 8S, 9‐epoxy‐CBD as intermediates, respectively, identified by us. Both metabolites have some pharmacological effects comparable to Δ9‐THC. Cannabinol (CBN), the other major component, was mainly metabolized to 11‐hydroxy‐CBN by hepatic microsomes of animals including humans. The pharmacological effects of the metabolite were higher than those of CBN demonstrating that 11‐hydroxylation of CBN is an activation pathway of the cannabinoid as is the case in THCs. Tolerance developed to catalepsy, hypothermia and pentobarbital‐induced sleep prolonging effects of Δ8‐THC and its active metabolite, 11‐hydroxy‐Δ8‐THC. Reciprocal cross‐tolerance also developed to pharmacological effects and the magnitude of tolerance development produced by the metabolite was significantly higher than that by Δ8‐THC indicating that 11‐hydroxy‐Δ8‐THC has important role not only in the pharmacological effects but also its tolerance development of Δ8‐THC. THCs and their metabolites competed with the specific binding of CP‐55,940, an agonist of cannabinoid receptor, to synaptic membrane from bovine cerebral cortex. The Ki value of THCs and their metabolites were closely parallel to their pharmacological effects in mice. A novel cytochrome P450 (cyp2c29) was purified and identified for the first time by us as a major enzyme responsible for the metabolic activation of Δ8‐THC at the 11‐position in the mouse liver. cDNA of cyp2c29 was cloned from a mouse cDNA library and its sequence was determined. All of major P450s involving the metabolic activation of Δ8‐THC at the 11‐position are belonging to CYP2C subfamily in mammalian liver.Keywords
This publication has 12 references indexed in Scilit:
- A Novel Metabolite, an Oxepin Formed from Cannabidiol with Guinea-pig Hepatic MicrosomesJournal of Pharmacy and Pharmacology, 1995
- Involvement of CYP2C in the Metabolism of Cannabinoids by Human Hepatic Microsomes from an Old Woman.Biological & Pharmaceutical Bulletin, 1995
- cDNA cloning and sequence of CYP2C29 encoding P-450 MUT-2, a microsomal aldehyde oxygenaseBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1994
- A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomesBiochemical Pharmacology, 1993
- Structure of a cannabinoid receptor and functional expression of the cloned cDNANature, 1990
- Oxygenation mechanism in the oxidation of xenobiotic aldehyde to carboxylic acid by mouse hepatic microsomesBiochemical and Biophysical Research Communications, 1988
- THE PHARMACOLOGICAL ACTIVITY OF CANNABINOL AND ITS MAJOR METABOLITE, 11-HYDROXYCANNABINOLCHEMICAL & PHARMACEUTICAL BULLETIN, 1987
- Metabolic Activation of Marihuana Constituents: Relations to Pharmacological and Toxicological EffectsYAKUGAKU ZASSHI, 1986
- Development of tolerance and cross-tolerance to the cataleptogenic effects of Δ8-tetrahydrocannabinol and 11-hydroxy-Δ8-tetrahydrocannabinol in miceEuropean Journal of Pharmacology, 1983
- Comparison in mice of pharmacological effects of Δ8-tetrahydrocannabinol and its metabolites oxidized at 11-positionEuropean Journal of Pharmacology, 1980